A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

Clinical trial NCT02804763 · COMPLETED

Trial details

NCT number: NCT02804763
Sponsor: UCB Biopharma S.P.R.L.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Systemic Lupus Erythematosus (SLE)

Start date: 2016-06-02
Primary completion: 2018-05-31
Enrollment: 182

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.